Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab, PMID: 33079180
Antibodies to watch in 2020, PMID: 31847708
Antibodies to watch in 2021, PMID: 33459118
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications, PMID: 32599589
Antibodies to watch in 2019, PMID: 30516432
Clinical significance of chemokine receptor antagonists, PMID: 31903790
Advances in Long-Acting Agents for the Treatment of HIV Infection, PMID: 32180205
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy, PMID: 33485378
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology, PMID: 31292161
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme, PMID: 31747383
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19, PMID: 32511656
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14, PMID: 33186704
Antibody-based strategies in HIV therapy, PMID: 33045349
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update, PMID: 32264722
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab, PMID: 33521616
Anti-HIV-1 Antibodies: An Update, PMID: 32152957
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab, PMID: 33778462
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission, PMID: 34099693
New drugs, PMID: 18953271
The return of PRO 140, a CCR5-directed mAb, PMID: 29708899
PRO 140--a novel CCR5 co-receptor inhibitor, PMID: 19807678
Healthcare resource use among solid organ transplant recipients hospitalized with COVID-19, PMID: 33349940
[Functional diversity of myosin motors], PMID: 12166062
Monoclonal CCR5 antibody for treatment of people with HIV infection, PMID: 21154397
Biology of CCR5 and its role in HIV infection and treatment, PMID: 16905787
Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels, PMID: 33912796
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer, PMID: 32130619
Vascular Patterning as Integrative Readout of Complex Molecular and Physiological Signaling by VESsel GENeration Analysis, PMID: 33839725
Fear acquisition and extinction deficits in amnestic mild cognitive impairment and early Alzheimer's disease, PMID: 31843256
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection, PMID: 25063928
Initial results for PRO 140, PMID: 16283839
Trials begin for PRO 140, PMID: 15635750
Entry inhibitor combination shows promise, PMID: 11228623
Phase 2 clinical trials started on PRO 140, PMID: 18273941
Anti-HIV agents. PRO 140--a receptor antibody for HIV, PMID: 18041151
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice, PMID: 29128556
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection, PMID: 29676212
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody, PMID: 20377413
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults, PMID: 20660677
A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src, PMID: 12649175
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults, PMID: 18771406
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140), PMID: 16890780
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1, PMID: 17005807
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C, PMID: 12634405
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial., PMID:39972543
Interventions for the management of long covid (post-covid condition): living systematic review., PMID:39603702
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19., PMID:39353749
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques., PMID:39324549
Is preexisting inflamed jaw marrow a "hidden" co-morbidity affecting outcomes of COVID-19 infections? - Clinical comparative study., PMID:38889772
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial., PMID:38545090
The Role and Therapeutic Targeting of CCR5 in Breast Cancer., PMID:37759462
Monoclonal CCR5 Antibody: A Promising Therapy for HIV., PMID:36927434
Editorial: CCR5: A receptor at the center stage in infection., PMID:36330512
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome., PMID:35452519
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species., PMID:35358290
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects., PMID:34999223
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab., PMID:34868084
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission., PMID:34099693
Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels., PMID:33912796
Vascular Patterning as Integrative Readout of Complex Molecular and Physiological Signaling by VESsel GENeration Analysis., PMID:33839725
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab., PMID:33778462
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab., PMID:33521616
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy., PMID:33485378
Antibodies to watch in 2021., PMID:33459118
Healthcare resource use among solid organ transplant recipients hospitalized with COVID-19., PMID:33349940
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14., PMID:33186704
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab., PMID:33079180
Antibody-based strategies in HIV therapy., PMID:33045349
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications., PMID:32599589
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19., PMID:32511656
A review of antibody-based therapeutics targeting G protein-coupled receptors: an update., PMID:32264722
Advances in Long-Acting Agents for the Treatment of HIV Infection., PMID:32180205
Anti-HIV-1 Antibodies: An Update., PMID:32152957
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer., PMID:32130619
Clinical significance of chemokine receptor antagonists., PMID:31903790
Antibodies to watch in 2020., PMID:31847708
Fear acquisition and extinction deficits in amnestic mild cognitive impairment and early Alzheimer's disease., PMID:31843256
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme., PMID:31747383
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology., PMID:31292161
Antibodies to watch in 2019., PMID:30516432
The return of PRO 140, a CCR5-directed mAb., PMID:29708899
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection., PMID:29676212
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice., PMID:29128556
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection., PMID:25063928
Monoclonal CCR5 antibody for treatment of people with HIV infection., PMID:21154397
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults., PMID:20660677
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody., PMID:20377413
PRO 140--a novel CCR5 co-receptor inhibitor., PMID:19807678
New drugs., PMID:18953271
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults., PMID:18771406
Phase 2 clinical trials started on PRO 140., PMID:18273941
Anti-HIV agents. PRO 140--a receptor antibody for HIV., PMID:18041151
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1., PMID:17005807
Biology of CCR5 and its role in HIV infection and treatment., PMID:16905787
For research use only. Not for human or drug use.
